Trial Profile
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs ICT 107 (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms STING
- Sponsors ImmunoCellular Therapeutics
- 29 Mar 2023 Planned number of patients changed from 542 to 234.
- 29 Mar 2023 Planned End Date changed from 1 Dec 2021 to 1 Dec 2025.
- 29 Mar 2023 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2025.